• Synonyms：
  DSPE-PEG-NHS
  
• Purity：
  ≥95%
• Recommended Storage Condition：
  Store at -5°C,keep in dry and avoid sunlight.
• Uses：
  Applicated in medical research, drug-release, nanotechnology and new materials research, cell culture. In the study of ligand, polypeptide synthesis support, a graft polymer compounds, new materials, and polyethylene glycol-modified functional coatings and other aspects of the active compound.

DSPE-PEG-SC, also known as DSPE-PEG-NHS, is a lipid-based PEG derivative commonly used in the formulation of liposomes and other lipid-based drug delivery systems. It contains succinimidyl ester groups, which are reactive toward primary amines, enabling conjugation with various targeting molecules such as antibodies, aptamers, proteins, and peptides. These targeting molecules are often employed to deliver drugs specifically to target cells or tissues, enhancing therapeutic efficacy while reducing off-target effects. By incorporating DSPE-PEG-SC into liposomal formulations, it helps extend circulating half-life, reduce non-specific protein binding, and minimize cell adhesion, resulting in improved drug delivery efficiency and enhanced therapeutic outcomes.

Biopharma PEG offers a wide range of PEG products from lab to commercial scale in both non-GMP and GMP grades. Email at sales@biochempeg.com and start using a superior product for your next product R&D project.

Cited Publications

This PEG derivative has been cited in peer-reviewed scientific publications. Browse the references below to learn more.

1. Richard Nii Lante Lamptey, Chengwen Sun, Jagdish Singh, Intranasal administration of angiotensin receptor shRNA to brain lowers blood pressure in spontaneously hypertensive rats, Biomedicine & Pharmacotherapy, Volume 182, 2025, 117790, ISSN 0753-3322, https://doi.org/10.1016/j.biopha.2024.117790.
2. Lubitz, L.J.; Haffner, M.P.; Rieger, H.; Leneweit, G. Elevated Cellular Uptake of Succinimide- and Glucose-Modified Liposomes for Blood–Brain Barrier Transfer and Glioblastoma Therapy. Biomedicines 2024, 12, 2135. https://doi.org/10.3390/biomedicines12092135 
3. Blood pressure reduction through brain delivery of nanoparticles loaded with plasmid DNA encoding angiotensin receptor shRNA, Lamptey, Richard Nii Lante et al., Molecular Therapy Nucleic Acids, Volume 35, Issue 2, 102210, https://doi.org/10.1016/j.omtn.2024.102210 
4. Chaeeun Bang, Min Gyu Park, In Kyung Cho, Da-Eun Lee, Gye Lim Kim, Eun Hyang Jang, Man Kyu Shim, Hong Yeol Yoon, Sangmin Lee, Jong-Ho Kim. Liposomes targeting the cancer cell-exposed receptor, claudin-4, for pancreatic cancer chemotherapy. Biomater Res. 2023;27:53.DOI:10.1186/s40824-023-00394-7 
5. Lamptey RNL, Sun C, Singh J. Brain-targeted delivery of losartan through functionalized liposomal nanoparticles for management of neurogenic hypertension. Int J Pharm. 2023;637:122841. doi:10.1016/j.ijpharm.2023.122841 
6. Arora, S., Kanekiyo, T., & Singh, J. (2022). Functionalized nanoparticles for brain targeted BDNF gene therapy to rescue Alzheimer's disease pathology in transgenic mouse model. International Journal of Biological Macromolecules, 208, 901-911. https://doi.org/10.1016/j.ijbiomac.2022.03.203

View more publications citing Biopharma PEG products.